Beta-agonists, beta-blockers and obstructive airway disease.
Madalena Esteves
Maria
M
meste@oninet.pt
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000402:Airway Obstruction / Q000188:drug therapy* / Q000209:etiology; D001249:Asthma / Q000150:complications / Q000188:drug therapy; D001986:Bronchial Spasm / Q000139:chemically induced / Q000401:mortality; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016022:Case-Control Studies; D000075202:Contraindications; D004311:Double-Blind Method; D004347:Drug Interactions; D006331:Heart Diseases / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D008171:Lung Diseases / Q000139:chemically induced / Q000188:drug therapy; D015201:Meta-Analysis as Topic; D017410:Practice Guidelines as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D015290:Second Messenger Systems / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D001993:Bronchodilator Agents